-
2
-
-
84940173230
-
Incidence and mortality of colorectal cancer in China, 2011
-
PID: 25717222
-
Liu S, Zheng R, Zhang M et al (2015) Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res 27:22–28
-
(2015)
Chin J Cancer Res
, vol.27
, pp. 22-28
-
-
Liu, S.1
Zheng, R.2
Zhang, M.3
-
3
-
-
84958940813
-
Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
-
Morand Bounaix, du Puch C, Nouaille M, Giraud S et al (2016) Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. J Transl Med 14:10
-
(2016)
J Transl Med
, vol.14
, pp. 10
-
-
Morand, B.1
du Puch, C.2
Nouaille, M.3
Giraud, S.4
-
4
-
-
84922754254
-
A review of the evolution of systemic chemotherapy in the management of colorectal cancer
-
COI: 1:CAS:528:DC%2BC2MXovVyhsbk%3D, PID: 25579803
-
Gustavsson B, Carlsson G, Machover D et al (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14:1–10
-
(2015)
Clin Colorectal Cancer
, vol.14
, pp. 1-10
-
-
Gustavsson, B.1
Carlsson, G.2
Machover, D.3
-
5
-
-
84951827874
-
Pharmacologic resistance in colorectal cancer: a review
-
COI: 1:CAS:528:DC%2BC28XotValsrk%3D, PID: 26753006
-
Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8:57–84
-
(2016)
Ther Adv Med Oncol
, vol.8
, pp. 57-84
-
-
Hammond, W.A.1
Swaika, A.2
Mody, K.3
-
6
-
-
78650233991
-
Chemotherapy of metastatic colorectal cancer
-
19(109):219–224
-
(2010) Chemotherapy of metastatic colorectal cancer. Prescrire Int 19(109):219–224
-
(2010)
Prescrire Int
-
-
-
7
-
-
84981309787
-
Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX
-
Kim MJ, Han SW, Lee DW et al (2016) Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat. doi:10.4143/crt.2015.296
-
(2016)
Cancer Res Treat
-
-
Kim, M.J.1
Han, S.W.2
Lee, D.W.3
-
8
-
-
84893868630
-
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB
-
COI: 1:CAS:528:DC%2BC2cXhtV2ltbg%3D, PID: 24173769
-
Yu M, Tong X, Qi B et al (2014) Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep 9:249–254
-
(2014)
Mol Med Rep
, vol.9
, pp. 249-254
-
-
Yu, M.1
Tong, X.2
Qi, B.3
-
9
-
-
78649307699
-
Pharmacogenetics of irinotecan disposition and toxicity: a review
-
COI: 1:CAS:528:DC%2BC3cXhtVOmu7%2FI, PID: 20406168
-
Fujita K, Sparreboom A (2010) Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 5:209–217
-
(2010)
Curr Clin Pharmacol
, vol.5
, pp. 209-217
-
-
Fujita, K.1
Sparreboom, A.2
-
10
-
-
33750583902
-
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
-
PID: 17008691
-
O’Dwyer PJ, Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534–4538
-
(2006)
J Clin Oncol
, vol.24
, pp. 4534-4538
-
-
O’Dwyer, P.J.1
Catalano, R.B.2
-
11
-
-
66349133649
-
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
-
COI: 1:CAS:528:DC%2BD1MXmvVOhsL0%3D, PID: 19364970
-
Cecchin E, Innocenti F, D’Andrea M et al (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457–2465
-
(2009)
J Clin Oncol
, vol.27
, pp. 2457-2465
-
-
Cecchin, E.1
Innocenti, F.2
D’Andrea, M.3
-
12
-
-
84948993611
-
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
-
COI: 1:CAS:528:DC%2BC28XlvVCqtbs%3D, PID: 26604633
-
Fujita K, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21:12234–12248
-
(2015)
World J Gastroenterol
, vol.21
, pp. 12234-12248
-
-
Fujita, K.1
Kubota, Y.2
Ishida, H.3
Sasaki, Y.4
-
13
-
-
84876327926
-
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy
-
COI: 1:CAS:528:DC%2BC3sXktVGisb4%3D, PID: 23303296
-
Inoue K, Sonobe M, Kawamura Y et al (2013) Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 229:107–114
-
(2013)
Tohoku J Exp Med
, vol.229
, pp. 107-114
-
-
Inoue, K.1
Sonobe, M.2
Kawamura, Y.3
-
14
-
-
84907451342
-
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
-
COI: 1:CAS:528:DC%2BC2cXhvFyit7zN, PID: 25175642
-
Tsunedomi R, Hazama S, Fujita Y et al (2014) A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 45:1381–1390
-
(2014)
Int J Oncol
, vol.45
, pp. 1381-1390
-
-
Tsunedomi, R.1
Hazama, S.2
Fujita, Y.3
-
15
-
-
79960320017
-
Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent
-
COI: 1:CAS:528:DC%2BC3MXhtFSrsLnM, PID: 22866151
-
Fukui T, Mitsufuji H, Kubota M et al (2011) Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2:923–928
-
(2011)
Oncol Lett
, vol.2
, pp. 923-928
-
-
Fukui, T.1
Mitsufuji, H.2
Kubota, M.3
-
16
-
-
12244271026
-
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
-
COI: 1:CAS:528:DC%2BD38XptFOqsbg%3D, PID: 12464801
-
Innocenti F, Grimsley C, Das S et al (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725–733
-
(2002)
Pharmacogenetics
, vol.12
, pp. 725-733
-
-
Innocenti, F.1
Grimsley, C.2
Das, S.3
-
17
-
-
14044279224
-
Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American
-
COI: 1:CAS:528:DC%2BD2MXisFSgt74%3D, PID: 15572581
-
Kaniwa N, Kurose K, Jinno H et al (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab Dispos 33:458–465
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 458-465
-
-
Kaniwa, N.1
Kurose, K.2
Jinno, H.3
-
18
-
-
85027955716
-
The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions
-
COI: 1:CAS:528:DC%2BC3cXpt1yru7w%3D, PID: 20511137
-
Marques SC, Ikediobi ON (2010) The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics 4:238–249
-
(2010)
Hum Genomics
, vol.4
, pp. 238-249
-
-
Marques, S.C.1
Ikediobi, O.N.2
-
19
-
-
84897383948
-
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
-
COI: 1:CAS:528:DC%2BC3sXksFOlsL4%3D, PID: 23529007
-
Liu X, Cheng D, Kuang Q, Liu G, Xu W (2014) Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 14:120–129
-
(2014)
Pharmacogenomics J
, vol.14
, pp. 120-129
-
-
Liu, X.1
Cheng, D.2
Kuang, Q.3
Liu, G.4
Xu, W.5
-
20
-
-
84893319290
-
The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
-
COI: 1:CAS:528:DC%2BC2cXhs1Wnsb4%3D, PID: 24308720
-
Chen YJ, Hu F, Li CY et al (2014) The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers 19:56–62
-
(2014)
Biomarkers
, vol.19
, pp. 56-62
-
-
Chen, Y.J.1
Hu, F.2
Li, C.Y.3
-
21
-
-
0038351780
-
The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications
-
COI: 1:CAS:528:DC%2BD3sXlt1aqsrk%3D, PID: 12850492
-
Premawardhena A, Fisher CA, Liu YT et al (2003) The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 31:98–101
-
(2003)
Blood Cells Mol Dis
, vol.31
, pp. 98-101
-
-
Premawardhena, A.1
Fisher, C.A.2
Liu, Y.T.3
-
22
-
-
34748857912
-
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations
-
COI: 1:CAS:528:DC%2BD2sXhtVOrtLnN, PID: 17060921
-
Zhang A, Xing Q, Qin S et al (2007) Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J 7:333–338
-
(2007)
Pharmacogenomics J
, vol.7
, pp. 333-338
-
-
Zhang, A.1
Xing, Q.2
Qin, S.3
-
23
-
-
34250665419
-
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
-
COI: 1:CAS:528:DC%2BD2sXnvFKnsb0%3D, PID: 17406868
-
Fujita K, Ando Y, Nagashima F et al (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60:515–522
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 515-522
-
-
Fujita, K.1
Ando, Y.2
Nagashima, F.3
-
24
-
-
84889593378
-
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
-
COI: 1:CAS:528:DC%2BC3sXhvVyksrbE, PID: 24033692
-
Hazama S, Mishima H, Tsunedomi R et al (2013) UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104:1662–1669
-
(2013)
Cancer Sci
, vol.104
, pp. 1662-1669
-
-
Hazama, S.1
Mishima, H.2
Tsunedomi, R.3
-
25
-
-
84953343664
-
UGT1A1 genotyping for proper use of irinotecan
-
PID: 26591441
-
Matsuoka A, Ando Y (2015) UGT1A1 genotyping for proper use of irinotecan. Rinsho Byori 63:876–882
-
(2015)
Rinsho Byori
, vol.63
, pp. 876-882
-
-
Matsuoka, A.1
Ando, Y.2
-
26
-
-
0030693602
-
Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study
-
COI: 1:STN:280:DyaK1c%2FgtVOmtQ%3D%3D, PID: 9382402
-
Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ (1997) Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med 127:813–816
-
(1997)
Ann Intern Med
, vol.127
, pp. 813-816
-
-
Cleeland, C.S.1
Gonin, R.2
Baez, L.3
Loehrer, P.4
Pandya, K.J.5
-
27
-
-
4344702304
-
Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0
-
PID: 15332541
-
Kaba H, Fukuda H, Yamamoto S, Ohashi Y (2004) Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho 31:1187–1192
-
(2004)
Gan To Kagaku Ryoho
, vol.31
, pp. 1187-1192
-
-
Kaba, H.1
Fukuda, H.2
Yamamoto, S.3
Ohashi, Y.4
-
28
-
-
77955591119
-
Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know
-
PID: 20651182
-
Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 195:281–289
-
(2010)
AJR Am J Roentgenol
, vol.195
, pp. 281-289
-
-
Nishino, M.1
Jagannathan, J.P.2
Ramaiya, N.H.3
Van den Abbeele, A.D.4
-
29
-
-
84949680996
-
The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
-
PID: 26664141
-
Xiao XG, Xia S, Zou M et al (2015) The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 8:3575–3583
-
(2015)
Onco Targets Ther
, vol.8
, pp. 3575-3583
-
-
Xiao, X.G.1
Xia, S.2
Zou, M.3
-
30
-
-
84876711885
-
UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer
-
COI: 1:CAS:528:DC%2BC3sXktFekt7c%3D, PID: 22934695
-
Zhou CF, Ma T, Su Y et al (2013) UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem 13:235–241
-
(2013)
Anticancer Agents Med Chem
, vol.13
, pp. 235-241
-
-
Zhou, C.F.1
Ma, T.2
Su, Y.3
-
31
-
-
84908667178
-
Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs
-
Chantry AS, Quaranta S, Ciccolini J, Lacarelle B (2014) Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs. Ann Biol Clin (Paris) 72:527–542
-
(2014)
Ann Biol Clin (Paris)
, vol.72
, pp. 527-542
-
-
Chantry, A.S.1
Quaranta, S.2
Ciccolini, J.3
Lacarelle, B.4
-
32
-
-
85006186477
-
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
-
COI: 1:CAS:528:DC%2BC28XlslWitb0%3D, PID: 26806397
-
Chibaudel B, Maindrault-Goebel F, Bachet JB et al (2016) PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med 5:676–683
-
(2016)
Cancer Med
, vol.5
, pp. 676-683
-
-
Chibaudel, B.1
Maindrault-Goebel, F.2
Bachet, J.B.3
-
33
-
-
26444594410
-
Clinical pharmacogenetics of irinotecan (CPT-11)
-
COI: 1:CAS:528:DC%2BD2MXhtFyqu7fF, PID: 16257834
-
Ando Y, Hasegawa Y (2005) Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 37:565–574
-
(2005)
Drug Metab Rev
, vol.37
, pp. 565-574
-
-
Ando, Y.1
Hasegawa, Y.2
-
34
-
-
84902936865
-
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801)
-
COI: 1:CAS:528:DC%2BC2cXhtFOqt7fI, PID: 24968756
-
Soeda H, Shimodaira H, Gamoh M et al (2014) Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Oncology 87:7–20
-
(2014)
Oncology
, vol.87
, pp. 7-20
-
-
Soeda, H.1
Shimodaira, H.2
Gamoh, M.3
-
35
-
-
84896051392
-
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
-
COI: 1:CAS:528:DC%2BC2cXhtVymt7s%3D, PID: 24448639
-
Cheng L, Li M, Hu J et al (2014) UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 73:551–560
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 551-560
-
-
Cheng, L.1
Li, M.2
Hu, J.3
-
36
-
-
84873906813
-
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
-
COI: 1:CAS:528:DC%2BC38XhvVyisLnP, PID: 23236239
-
Wang Y, Shen L, Xu N et al (2012) UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 18:6635–6644
-
(2012)
World J Gastroenterol
, vol.18
, pp. 6635-6644
-
-
Wang, Y.1
Shen, L.2
Xu, N.3
-
37
-
-
84957991755
-
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients
-
COI: 1:CAS:528:DC%2BC28Xislakt7k%3D, PID: 26830078
-
Atasilp C, Chansriwong P, Sirachainan E et al (2016) Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet 31:90–94
-
(2016)
Drug Metab Pharmacokinet
, vol.31
, pp. 90-94
-
-
Atasilp, C.1
Chansriwong, P.2
Sirachainan, E.3
-
38
-
-
84954076213
-
Development of pyrosequencing method for detection of UGT1A1 polymorphisms in thai colorectal cancers
-
COI: 1:CAS:528:DC%2BC28XhtV2jtrs%3D, PID: 25545261
-
Sukasem C, Atasilp C, Chansriwong P et al (2016) Development of pyrosequencing method for detection of UGT1A1 polymorphisms in thai colorectal cancers. J Clin Lab Anal 30:84–89
-
(2016)
J Clin Lab Anal
, vol.30
, pp. 84-89
-
-
Sukasem, C.1
Atasilp, C.2
Chansriwong, P.3
-
39
-
-
0028420933
-
Direct sequencing of PCR-amplified DNA
-
COI: 1:CAS:528:DyaK2MXhsVOruw%3D%3D, PID: 7859155
-
Green PM, Giannelli F (1994) Direct sequencing of PCR-amplified DNA. Mol Biotechnol 1:117–124
-
(1994)
Mol Biotechnol
, vol.1
, pp. 117-124
-
-
Green, P.M.1
Giannelli, F.2
-
40
-
-
44849107763
-
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity
-
COI: 1:CAS:528:DC%2BD1cXnvVagurs%3D, PID: 18467239
-
Biason P, Masier S, Toffoli G (2008) UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother 20:158–165
-
(2008)
J Chemother
, vol.20
, pp. 158-165
-
-
Biason, P.1
Masier, S.2
Toffoli, G.3
-
41
-
-
84878637878
-
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
-
COI: 1:CAS:528:DC%2BC3sXovVejs74%3D, PID: 23543295
-
Cortejoso L, Garcia MI, Garcia-Alfonso P et al (2013) Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol 71:1463–1472
-
(2013)
Cancer Chemother Pharmacol
, vol.71
, pp. 1463-1472
-
-
Cortejoso, L.1
Garcia, M.I.2
Garcia-Alfonso, P.3
-
42
-
-
84908159566
-
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
-
COI: 1:CAS:528:DC%2BC2cXitFOltbrL, PID: 25285015
-
Li M, Wang Z, Guo J et al (2014) Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 7:1653–1661
-
(2014)
Onco Targets Ther
, vol.7
, pp. 1653-1661
-
-
Li, M.1
Wang, Z.2
Guo, J.3
-
43
-
-
84905117637
-
Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan
-
COI: 1:CAS:528:DC%2BC2MXovFCitQ%3D%3D, PID: 24977443
-
Boyer JC, Etienne-Grimaldi MC, Thomas F et al (2014) Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. Bull Cancer 101:533–553
-
(2014)
Bull Cancer
, vol.101
, pp. 533-553
-
-
Boyer, J.C.1
Etienne-Grimaldi, M.C.2
Thomas, F.3
-
44
-
-
59849128188
-
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
-
COI: 1:CAS:528:DC%2BD1MXlvFenuw%3D%3D, PID: 19125129
-
Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD (2009) Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11:21–34
-
(2009)
Genet Med
, vol.11
, pp. 21-34
-
-
Palomaki, G.E.1
Bradley, L.A.2
Douglas, M.P.3
Kolor, K.4
Dotson, W.D.5
-
45
-
-
33745972934
-
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
-
COI: 1:CAS:528:DC%2BD28XnslKhs7w%3D, PID: 16809730
-
Toffoli G, Cecchin E, Corona G et al (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061–3068
-
(2006)
J Clin Oncol
, vol.24
, pp. 3061-3068
-
-
Toffoli, G.1
Cecchin, E.2
Corona, G.3
-
46
-
-
73449111242
-
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
-
COI: 1:CAS:528:DC%2BD1MXhtlOhtLnM, PID: 19859999
-
Schulz C, Heinemann V, Schalhorn A et al (2009) UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 15:5058–5066
-
(2009)
World J Gastroenterol
, vol.15
, pp. 5058-5066
-
-
Schulz, C.1
Heinemann, V.2
Schalhorn, A.3
-
47
-
-
84875024320
-
Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians
-
COI: 1:CAS:528:DC%2BC3sXltVSqu74%3D, PID: 23516488
-
Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS ONE 8:e58489
-
(2013)
PLoS ONE
, vol.8
, pp. e58489
-
-
Liu, X.1
Cheng, D.2
Kuang, Q.3
Liu, G.4
Xu, W.5
|